OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML
Top Cited Papers
- 9 May 2013
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (19), 1781-1790
- https://doi.org/10.1056/nejmoa1214514
Abstract
The molecular causes of many hematologic cancers remain unclear. Among these cancers are chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) chronic myeloid leukemia (CML), both of which are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic drivers that are known to occur in other myeloproliferative neoplasms and myeloproliferative–myelodysplastic overlap neoplasms. To identify potential genetic drivers in these disorders, we used an integrated approach of deep sequencing coupled with the screening of primary leukemia cells obtained from patients with CNL or atypical CML against panels of tyrosine kinase–specific small interfering RNAs or small-molecule kinase inhibitors. We validated candidate oncogenes using in vitro transformation assays, and drug sensitivities were validated with the use of assays of primary-cell colonies. We identified activating mutations in the gene encoding the receptor for colony-stimulating factor 3 (CSF3R) in 16 of 27 patients (59%) with CNL or atypical CML. These mutations segregate within two distinct regions of CSF3R and lead to preferential downstream kinase signaling through SRC family–TNK2 or JAK kinases and differential sensitivity to kinase inhibitors. A patient with CNL carrying a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK1/2 inhibitor ruxolitinib. Mutations in CSF3R are common in patients with CNL or atypical CML and represent a potentially useful criterion for diagnosing these neoplasms. (Funded by the Leukemia and Lymphoma Society and others.)Keywords
This publication has 40 references indexed in Scilit:
- Recurrent SETBP1 mutations in atypical chronic myeloid leukemiaNature Genetics, 2012
- A truncation mutant of Csf3r cooperates with PML-RARα to induce acute myeloid leukemia in miceExperimental Hematology, 2011
- G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphataseBlood, 2011
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsBlood, 2010
- An activating mutation in the CSF3R gene induces a hereditary chronic neutrophiliaThe Journal of Experimental Medicine, 2009
- RNAi screen for rapid therapeutic target identification in leukemia patientsProceedings of the National Academy of Sciences of the United States of America, 2009
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Impaired Production and Increased Apoptosis of Neutrophils in Granulocyte Colony-Stimulating Factor Receptor–Deficient MiceImmunity, 1996